About Nervomartrix
As the developer of Auto-Targeting Neurostimulation (ATN) - a breakthrough solution for pain relief - Nervomatrix aims to become a key provider of non-invasive drug-free pain relief products designed for the pain clinicians' market.
An estimated $80 billion is spent annually in the United States due to back pain, and with lower back pain being the #1 cause for activity limitation in people under 45, as well as vast number of missed working days , there is a strong and growing demand for a drug free pain relief solution.
Founded by Miguel Gorenberg, M.D., Nervomatrix is funded by the Chief Scientist of the State of Israel and Startvest (2006) Limited Partnership, the investing partners of Targetech Innovation Center Incubator.
Stratvest is owned by two investing partners: ASG Finance Corp, a Canadian investment services firm with over $275M in assets managed, and Greater Akron Investing Partners (GAIP), a group of investors from the city and business community of Akron, Ohio. These include over 20 individual and institutional investors from the area, which due to institutional infrastructure such as the Cleveland Clinic, Summa Enterprises, Bioenterprises, Akron General and Children’s Hospitals, is well known for its expertise in Life Sciences.
Mr. Azriel Kadim
Mr. Zohar Gendler
Miguel Gorenberg, M.D.
Mr. Ori Kanner
Prof. Elon Eisenberg
2007-2010 Nervomatrix Ltd. All rights reserved. Nervomatrix Ltd. will not be liable for any damages of any kind arising out of or relating to the use or the inability to use the site, its content or links, including, but not limited to, special, incidental or consequential damages.